{"id":"NCT04620733","sponsor":"Gilead Sciences","briefTitle":"RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)","officialTitle":"RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-04-21","primaryCompletion":"2023-08-11","completion":"2023-08-11","firstPosted":"2020-11-09","resultsPosted":"2024-07-25","lastUpdate":"2024-09-05"},"enrollment":193,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Primary Biliary Cholangitis"],"interventions":[{"type":"DRUG","name":"Seladelpar 10 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Seladelpar 5 mg","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Seladelpar","type":"EXPERIMENTAL"}],"summary":"The purposes of this study are to evaluate the treatment effect of seladelpar on composite biochemical improvement in cholestasis markers based on ALP and total bilirubin and to evaluate the safety of seladelpar over 12 months of treatment compared to placebo.\n\nThe study also checked the effect of treatment on the symptoms of PBC, including pruritus.","primaryOutcome":{"measure":"Percentage of Participants With Response Criteria for the Composite Endpoint of ALP <1.67 × Upper Limit of Normal (ULN), ≥15% Reduction in ALP, and Total Bilirubin ≤ 1.0× ULN at Month 12","timeFrame":"Month 12","effectByArm":[{"arm":"Placebo","deltaMin":20,"sd":null},{"arm":"Seladelpar","deltaMin":61.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":17},"locations":{"siteCount":134,"countries":["United States","Argentina","Australia","Austria","Belgium","Canada","Chile","Czechia","Denmark","France","Germany","Greece","Hungary","Israel","Italy","Mexico","New Zealand","Poland","Romania","Russia","South Korea","Spain","Switzerland","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["38381664"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":65},"commonTop":["Covid-19","Pruritus","Fatigue","Nasopharyngitis","Arthralgia"]}}